TOKYO -- The Japanese government is on track to approve of Eli Lilly's popular obesity treatment Zepbound in the coming months, the head of the company told Nikkei Friday.
Pharmaceuticals
Eli Lilly obesity drug on track for Japan approval next year: CEO
Zepbound is currently under review by Japanese authorities, says David Ricks
Eli Lilly's Chair and CEO David Ricks says his company has the most candidates to treat obesity in its pipeline among all drugmakers. (Photo by Kosuke Imamura)
Read Next
Latest on Pharmaceuticals
